Ultragenyx Pharmaceutical Inc. (RARE) News
Follow Ultragenyx Pharmaceutical Inc. (RARE) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 64 public stories across 20 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Ultragenyx Cuts Workforce 20%, Targets 2027 Profitability
Ultragenyx plans to reduce its workforce by about 20% and lower operating expenses as it targets full-year GAAP profitability in 2027. The company also reported a third-quarter loss of $1.16 per share and revenue of $173
EARNINGS | Nov 04, 2026, 02:15 PM UTC
M
Ultragenyx Reports Third-Quarter Revenue of $173 Million
Revenue rose 8% year over year to $173 million. The company reported a net loss of $118 million and diluted loss per share of $1.16, compared with a $180 million loss and $1.81 per share a year earlier.
EQUITY | Nov 04, 2026, 11:12 AM UTC
M
Ultragenyx Q3 Loss Narrows as Revenue Rises; Shares Fall Pre-Bell
EQUITY | Nov 04, 2026, 09:32 AM UTC
M
Ultragenyx Reports Q3 Results, Plans 20% Workforce Reduction
Ultragenyx reported a third-quarter net loss of $118 million, narrowed from $180 million a year earlier, on revenue of $173 million. It reaffirmed 2026 revenue guidance of $730 million to $760 million, excluding new prod
EQUITY | Nov 03, 2026, 10:33 PM UTC
M
Ultragenyx reports Q3 loss of $1.16 per share
Ultragenyx posted a Q3 loss of $1.16 per share, versus a FactSet estimate for a $1.10 loss.
EQUITY | Nov 03, 2026, 10:27 PM UTC
M
Ultragenyx Pharmaceutical reports quarterly results for period ended September 30
A machine-generated LSEG summary reports results for the quarter ended September 30; no figures are provided in the available text.
EQUITY | Nov 03, 2026, 10:02 PM UTC
M
Ultragenyx Shares Fall 6% After Plans to Cut Staff, End Drug Projects
Ultragenyx said it would reduce its workforce and discontinue certain drug development programs. Shares fell 6% to $15.67 in after-hours trading Tuesday.
EQUITY | Nov 03, 2026, 10:00 PM UTC
M
Ultragenyx Q3 Revenue Rises as Net Loss Narrows
EQUITY | Nov 03, 2026, 09:12 PM UTC
M
Ultragenyx Terminates UX701 Wilson Disease Study After Goals Not Met
Ultragenyx Pharmaceutical is terminating its UX701 study for Wilson disease because it did not achieve study goals.
EQUITY | Nov 03, 2026, 09:07 PM UTC
M
Ultragenyx reaffirms FY2026 Crysvita revenue guidance at $500M-$520M
EARNINGS | Nov 03, 2026, 09:06 PM UTC
M
Ultragenyx Reports Third-Quarter 2026 Results, Cuts Expenses, Reaffirms 2027 Profitability
Ultragenyx reports third-quarter 2026 financial results, announces substantial expense reductions and reaffirms profitability in 2027.
EQUITY | Nov 03, 2026, 09:03 PM UTC
M
Ultragenyx reports Q3 net loss
EQUITY | Nov 03, 2026, 09:03 PM UTC
M
Ultragenyx Pharma Reports $173M in Third-Quarter Revenue
EQUITY | Nov 03, 2026, 09:02 PM UTC
M
Ultragenyx to Host Q3 2026 Results and Corporate Update Call
Ultragenyx announced a conference call for its third-quarter 2026 financial results and corporate update.
EQUITY | Oct 27, 2026, 08:09 PM UTC
M
Ultragenyx to Sell Priority Review Voucher for $203 Million
Ultragenyx Pharmaceutical said it is selling a rare pediatric disease priority review voucher for $203 million.
EQUITY | Oct 14, 2026, 02:17 PM UTC
M
Ultragenyx to Sell FDA Priority Review Voucher for $203 Million
Ultragenyx entered an asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher for $203 million in cash at closing. The voucher was awarded after FDA approval of FAYUVI (UX111) for MPS IIIA. Th
EQUITY | Oct 14, 2026, 01:03 PM UTC
L
Ultragenyx agrees to sell priority review voucher for $203 million
Ultragenyx entered into an agreement to sell a Rare Pediatric Disease Priority Review Voucher for $203 million.
EQUITY | Oct 14, 2026, 12:30 PM UTC
L
Weekly Recap: Fayuvi FDA approval at $3.95M and GTX-102 program halt
Ultragenyx Pharmaceutical, Inc. (NASDAQ:RARE) is advancing with FDA approval and imminent shipment of Fayuvi for Sanfilippo A at a roughly $3.95M list price while simultaneously cutting costs after halting and discontinu
REGULATION | Sep 28, 2026, 11:06 AM UTC
M
Ultragenyx Q2 revenue $214M, reiterates 2027 profitability goal
Ultragenyx (RARE) reported Q2 revenue of $214M and reiterated its 2027 profitability goal. The company said it won FDA approvals for FAYUVI and Genglycos, halted GTX-102 for Angelman after a failed Phase 3, and cut costs
EQUITY | Sep 21, 2026, 11:29 AM UTC
M
Cantor lifts Ultragenyx price target after FDA Fayuvi approval
TradingView News reports Cantor raised its price target after the U.S. FDA approved Fayuvi to treat children with Sanfilippo syndrome Type A; Ultragenyx (RARE) was in focus amid “price-target hikes.”
EARNINGS | Sep 18, 2026, 12:17 PM UTC
M
ABEO rises after Roth Capital initiates Buy; Fayuvi FDA approval
ABEO closed up 4% Thursday and added 2% after-hours after Roth Capital initiated coverage at Buy with a $17 target; Ultragenyx’s Fayuvi gene therapy received late-session FDA approval.
EQUITY | Sep 17, 2026, 11:33 PM UTC
H
RARE shares jump 13% after-hours following FDA approval
Ultragenyx Pharmaceutical’s RARE stock extended after-hours gains after U.S. regulators approved Fayuvi, the first treatment for Sanfilippo syndrome type A.
REGULATION | Sep 17, 2026, 10:37 PM UTC
M
US stocks rise as oil stabilizes and inflation worries ease
The Dow Jones Industrial Average rose 316.14 points, or 0.61%, to 51778.04, while the S&P 500 gained 85.95 points, or 1.14%, to 7637.76.
EQUITY | Sep 17, 2026, 08:48 PM UTC
H
Ultragenyx stock jumps after FDA approves Fayuvi for Sanfilippo A
FDA approval of Ultragenyx Pharmaceutical’s Fayuvi for children with Sanfilippo syndrome type A sent the shares up about 12% to $14.44 late Thursday.
EQUITY | Sep 17, 2026, 07:53 PM UTC
M
RARE falls to fresh 52-week low as FDA decision nears
Ultragenyx Pharmaceutical shares slipped and hit a fresh 52-week low ahead of an FDA decision this week on UX111, a one-time gene therapy for Sanfilippo syndrome type A. The stock fell as much as 1.45% intraday.
EQUITY | Sep 16, 2026, 07:38 PM UTC
M
Ultragenyx shares plunge after apazunersen Phase 3 misses endpoints
Ultragenyx Pharmaceutical’s shares fell after Phase 3 apazunersen for Angelman missed key endpoints, triggering a program review and cost cuts. Positive GENGLYCOS data and upcoming UX111 and gene-therapy readouts keep fo
EQUITY | Sep 07, 2026, 11:22 AM UTC
M
Goldman Sachs cuts Ultragenyx Pharma price target to $19.00
Goldman Sachs reduced its price target for Ultragenyx Pharma to $19.00 per share from $28.00, while maintaining its rating at Neutral.
EQUITY | Sep 04, 2026, 06:08 PM UTC
L
Barclays maintains RARE at Overweight
Barclays maintained a Overweight rating on RARE.
EQUITY | Sep 04, 2026, 12:55 PM UTC
H
RARE shares hit all-time low after failed Angelman syndrome trial
Ultragenyx Pharmaceutical (RARE) logged its worst trading day on record and closed at an all-time low Thursday after its Angelman syndrome treatment failed a key trial, triggering Wall Street target cuts and takeover spe
MNA | Sep 04, 2026, 07:25 AM UTC
H
NIO, RARE and MCD hit 52-week lows amid negative catalysts
NIO, Ultragenyx Pharmaceutical (RARE) and McDonald's (MCD) plunged to 52-week lows. TradingView News cites negative catalysts and price target cuts, with NIO down 0.3% after Q2 results that fell short of expectations.
EARNINGS | Sep 04, 2026, 04:23 AM UTC
L
JP Morgan cuts Ultragenyx Pharma to Neutral
JP Morgan downgraded Ultragenyx Pharma to Neutral from Overweight.
EQUITY | Sep 03, 2026, 09:08 PM UTC
L
Jefferies maintains Buy on Ultragenyx Pharma
Jefferies maintained a Buy rating on Ultragenyx Pharma, according to TradingView News.
EQUITY | Sep 03, 2026, 09:02 PM UTC
L
RARE downgraded to market perform from outperform by William Blair
William Blair has cut Ultragenyx Pharma’s rating on RARE to market perform from outperform, according to TradingView News via Benzinga ratings actions.
EQUITY | Sep 03, 2026, 07:43 PM UTC
L
Citigroup cuts Ultragenyx Pharma price target to $28.00
Citigroup cut its price target for Ultragenyx Pharma to $28.00 per share from $58.00, while maintaining a Buy rating, according to Benzinga.
EQUITY | Sep 03, 2026, 04:32 PM UTC
H
Gold jumps 3% as ISM services PMI rises in August
The ISM services PMI surged to 55.4 in August from 54.1 previously, above the 54.3 market estimate and its strongest pace in six months.
MACRO | Sep 03, 2026, 04:05 PM UTC
L
Ultragenyx Pharma maintained Buy rating by TD Cowen
TD Cowen maintained a Buy rating on Ultragenyx Pharma, according to Benzinga ratings actions via TradingView News.
EQUITY | Sep 03, 2026, 03:52 PM UTC
L
Wells Fargo cuts Ultragenyx Pharma PT to $18 from $50
Wells Fargo lowered its price target on Ultragenyx Pharma to $18.00 per share from $50.00, according to ratings actions reported by Benzinga (via TradingView News).
EQUITY | Sep 03, 2026, 02:19 PM UTC
L
Canaccord Genuity cuts Ultragenyx Pharma PT to $37
Canaccord Genuity maintained a Buy rating on Ultragenyx Pharma while cutting its price target to $37.00 per share from $83.00.
EQUITY | Sep 03, 2026, 01:23 PM UTC
L
Wedbush maintains Ultragenyx Pharma neutral, cuts $23 target
Wedbush maintains a neutral rating on Ultragenyx Pharma and cuts its price target to $23.00 from $30.00, according to Benzinga ratings action summarized by TradingView News.
EQUITY | Sep 03, 2026, 01:21 PM UTC
L
Morning Market Movers: RARE, BIAF, TLYS, SNOW See Big Swings
BEIJING (dpa-AFX) - At 7:50 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening bell.For active traders, pr
EQUITY | Sep 03, 2026, 12:54 PM UTC
M
Evercore ISI cuts Ultragenyx Pharma PT to $16.00 from $34.00
Evercore ISI Group cut its price target for Ultragenyx Pharma to $16.00 per share from $34.00 and moved the rating to In-Line from Outperform, per Benzinga.
EQUITY | Sep 03, 2026, 12:25 PM UTC
L
Baird cuts Ultragenyx Pharma to Neutral, trims price target
Baird downgraded Ultragenyx Pharma to Neutral and cut its price target to $16.00 per share from $40.00, according to ratings actions reported by Benzinga.
EQUITY | Sep 03, 2026, 11:54 AM UTC
M
Ultragenyx shares fall 47% after GTX-102 misses late-stage goal
Ultragenyx’s stock sank 47% after its rare-disease drug candidate GTX-102 failed to meet its main goal in a late-stage trial, triggering a flurry of downgrades. Some analysts still cite pipeline potential.
EQUITY | Sep 03, 2026, 11:46 AM UTC
M
RARE shares plunge after Angelman late-stage trial failure, downgraded
Ultragenyx Pharmaceutical’s experimental Angelman syndrome therapy failed a key late-stage trial, triggering analyst downgrades and fresh concerns. RARE shares were down 45% in pre-market trading.
EQUITY | Sep 03, 2026, 10:50 AM UTC
L
Ultragenyx Pharma maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. maintained its Buy rating on Ultragenyx Pharma, according to Benzinga ratings actions reported by TradingView News.
EQUITY | Sep 03, 2026, 10:30 AM UTC
L
Cantor Fitzgerald maintains Overweight on Ultragenyx Pharma
Cantor Fitzgerald maintains an Overweight rating on Ultragenyx Pharma.
EQUITY | Sep 03, 2026, 09:29 AM UTC
M
Ultragenyx reviews apazunersen and plans cost cuts after Phase 3 miss
Ultragenyx said it will reduce expenses and evaluate its development of apazunersen after the drug failed to meet its primary endpoint in a Phase 3 trial, which targeted improved cognitive scores in Angelman syndrome pat
EQUITY | Sep 02, 2026, 09:14 PM UTC
M
Ultragenyx drug apazunersen misses main goal in late-stage trial
Ultragenyx Pharmaceutical said its experimental apazunersen for Angelman syndrome did not meet the main goal in a late-stage trial, sending shares down 40% in after-hours trading.
EQUITY | Sep 02, 2026, 08:18 PM UTC
M
Ultragenyx says Phase 3 Aspire missed primary, key secondary endpoints
Ultragenyx said Phase 3 Aspire of apazunersen in Angelman syndrome failed to meet its primary and key secondary endpoints.
REGULATION | Sep 02, 2026, 08:15 PM UTC
L
Ultragenyx Announces Phase 3 Aspire Results In Angelman Syndrome
Ultragenyx Pharmaceutical Inc. NASDAQ:RARE
EQUITY | Sep 02, 2026, 08:09 PM UTC
M
Ultragenyx drug fails late-stage trial main goal
Ultragenyx Pharmaceutical said its experimental drug for a rare genetic neurodevelopmental disorder did not meet the main goal in a late-stage trial.
EQUITY | Sep 02, 2026, 08:06 PM UTC
L
RARE - Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome
RARE - Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome
EQUITY | Sep 02, 2026, 08:01 PM UTC
L
RARE publishes GENGLYCOS 96-week GSDIa trial in Journal of Inherited Metabolic Disease
Ultragenyx (RARE) announced publication of a 96-week randomized, placebo-controlled trial of GENGLYCOS (DTX401) AAV gene therapy in GSDIa with crossover treatment.
EQUITY | Sep 01, 2026, 08:07 PM UTC
L
Ultragenyx Pharma Is Maintained at Overweight by Wells Fargo
Ultragenyx Pharma Is Maintained at Overweight by Wells Fargo
EQUITY | Aug 28, 2026, 04:57 PM UTC
L
Biotech Stocks Facing FDA Decision In September 2026
Biotech Stocks Facing FDA Decision In September 2026
REGULATION | Aug 26, 2026, 03:27 PM UTC
L
Crypto names, BULL, FUTU and RARE rise in premarket
Crypto names trade higher after Trump pushed for passage of the Clarity Act, while BULL rises 14% on earnings, FUTU 9% on earnings and RARE 8% on U.S. FDA approval of GENGLYCOS gene therapy.
EARNINGS | Aug 20, 2026, 01:13 PM UTC
H
BULL, FUTU rise premarket after earnings-linked news flow
BULL and FUTU are up 10% premarket on earnings-related news, while DE gains 4% on earnings and RARE rises 6% on U.S. FDA approval of GENGLYCOS gene therapy.
EARNINGS | Aug 20, 2026, 12:27 PM UTC
M
RARE raises PT to $58 on US accelerated approval of GENFLYCOS
RARE’s price target is raised to $58 from $45 following US accelerated approval of GENFLYCOS ahead of PDUFA, per Hammerstone MarketTalk at Citi.
EQUITY | Aug 20, 2026, 10:49 AM UTC
M
RARE secures US FDA approval for Genglycos gene therapy in GSDIa
RARE said the US FDA approved its gene therapy Genglycos to treat glycogen storage disease type Ia (GSDIa), also known as Von Gierke disease, in adults and pediatric patients.
EQUITY | Aug 20, 2026, 10:47 AM UTC
L
RARE - Link To Story from ULTRAGENYX.com
RARE - Link To Story from ULTRAGENYX.com
EQUITY | Aug 19, 2026, 09:39 PM UTC